{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:36:14Z","timestamp":1793478974498,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["ISM-51500"],"award-info":[{"award-number":["ISM-51500"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1136\/ard-2022-223429","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T13:20:15Z","timestamp":1677244815000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0173-0668","authenticated-orcid":false,"given":"Christian","family":"Dejaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6685-8873","authenticated-orcid":false,"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2108-0030","authenticated-orcid":false,"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-2955","authenticated-orcid":false,"given":"Milena","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Hysa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-6458","authenticated-orcid":false,"given":"Dario","family":"Camellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8737-001X","authenticated-orcid":false,"given":"Lisa","family":"Ehlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Abril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Appenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-6534","authenticated-orcid":false,"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-8834","authenticated-orcid":false,"given":"Christina","family":"Duftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8269-9438","authenticated-orcid":false,"given":"Peter C","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-6549","authenticated-orcid":false,"given":"Alojzija","family":"Ho\u010devar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-7321","authenticated-orcid":false,"given":"Tanaz A","family":"Kermani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-0124","authenticated-orcid":false,"given":"Eric L","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-1192","authenticated-orcid":false,"given":"Cristina","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-3148","authenticated-orcid":false,"given":"Carlo","family":"Salvarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-6828","authenticated-orcid":false,"given":"Sebastian Eduardo","family":"Sattui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-8738","authenticated-orcid":false,"given":"Wolfgang A","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-7049","authenticated-orcid":false,"given":"Carlos Enrique","family":"Toro-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223429_bib1","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223429_bib2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib3","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41584-020-0458-5","article-title":"Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica","volume":"16","author":"Camellino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223429_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"Recommendations for the management of polymyalgia rheumatica: a European league against rheumatism\/American college of rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib8","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American college of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib10","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223429_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2022-eular.5004a","article-title":"LB0006 SARILUMAB in patients with relapsing polymyalgia rheumatica: a phase 3, multicenter, randomized, double blind, placebo controlled trial (SAPHYR)","volume":"81","author":"Dasgupta","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.rdc.2019.07.005","article-title":"Treat to target: a valid concept for management of polymyalgia rheumatica and giant cell arteritis?","volume":"45","author":"Camellino","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1136\/ard-2022-223429_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib15","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223429_bib19","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. computer assisted management in early rheumatoid arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib20","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223429_bib21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011458","article-title":"Development of a critical appraisal tool to assess the quality of cross-sectional studies (axis)","volume":"6","author":"Downes","year":"2016","journal-title":"BMJ Open"},{"key":"10.1136\/ard-2022-223429_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223429_bib25","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223429_bib26","author":"EULAR"},{"key":"10.1136\/ard-2022-223429_bib27","author":"OCEBM Levels of Evidence Working Group"},{"key":"10.1136\/ard-2022-223429_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.semarthrit.2020.04.004","article-title":"Relapses and long-term remission in large vessel giant cell arteritis in northern italy: characteristics and predictors in a long-term follow-up study","volume":"50","author":"Muratore","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.5507\/bp.2015.026","article-title":"Various forms of (18) F-FDG PET and PET\/CT findings in patients with polymyalgia rheumatica","volume":"159","author":"Rehak","year":"2015","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1136\/ard-2022-223429_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3171\/2014.2.JNS131423","article-title":"Hoarding symptoms and prediction of poor response to limbic system surgery for treatment-refractory obsessive-compulsive disorder","volume":"121","author":"Gentil","year":"2014","journal-title":"J Neurosurg"},{"key":"10.1136\/ard-2022-223429_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/rheumatology\/kel376","article-title":"Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients","volume":"46","author":"Blockmans","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib32","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/fampra\/cmn044","article-title":"Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome","volume":"25","author":"Barraclough","year":"2008","journal-title":"Fam Pract"},{"key":"10.1136\/ard-2022-223429_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019320","article-title":"Challenges of diagnosis and management of giant cell arteritis in general practice: a multimethods study","volume":"8","author":"Helliwell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1136\/ard-2022-223429_bib34","first-page":"S103","article-title":"Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study","volume":"33","author":"Patil","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","article-title":"The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a more effective strategy to improve clinical outcome in giant cell arteritis?","volume":"55","author":"Diamantopoulos","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1120672120901693","article-title":"Vision-related and health-related quality of life in patients with giant cell arteritis","volume":"31","author":"N\u00ed Mh\u00e9al\u00f3id","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1136\/ard-2022-223429_bib37","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonz\u00e1lez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib40","first-page":"1","article-title":"Corticosteroids reduce vascular ultrasound sensitivity in fast- track pathways (FTP): results from coventry multi-disciplinary FTP for cranial giant cell arteritis","author":"Pinnell","year":"2022","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib41","article-title":"Validation of the southend giant cell arteritis probability score in a Scottish single-centre fast-track pathway","volume":"6","author":"Melville","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2022-223429_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/acr2.11346","article-title":"Vascular ultrasound for giant cell arteritis: establishing a protocol using vascular sonographers in a fast-track clinic in the United States","volume":"4","author":"Oshinsky","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105185","article-title":"Fast track clinic for early diagnosis of polymyalgia rheumatica: impact on symptom duration and prednisolone initiation","volume":"88","author":"Fr\u00f8lund","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2022-223429_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narv\u00e1ez","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MD.0b013e318145275c","article-title":"Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"86","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2007","journal-title":"Medicine"},{"key":"10.1136\/ard-2022-223429_bib46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.23901","article-title":"Prevalence of giant cell arteritis relapse in patients treated with glucocorticoids: a meta-analysis","volume":"72","author":"Mainbourg","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223429_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib48","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1017\/S1463423619000082","article-title":"The association of pain and stiffness with fatigue in incident polymyalgia rheumatica: baseline results from the polymyalgia rheumatica cohort study","volume":"20","author":"Prior","year":"2019","journal-title":"Prim Health Care Res Dev"},{"key":"10.1136\/ard-2022-223429_bib49","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102930","article-title":"Epidemiology of major relapse in giant cell arteritis: a study-level meta-analysis","volume":"21","author":"Aussedat","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-223429_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/OARRR.S213964","article-title":"A qualitative study of patient perspectives related to glucocorticoid therapy in polymyalgia rheumatica and giant cell arteritis","volume":"11","author":"Hoon","year":"2019","journal-title":"Open Access Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib52","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","article-title":"Comorbidities in polymyalgia rheumatica: a systematic review","volume":"20","author":"Partington","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223429_bib53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223429_bib54","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2022-222341","article-title":"2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases","volume":"81","author":"de Thurah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib55","series-title":"Polymyalgia rheumatica and giant cell arteritis: a survival guide","author":"Gilbert","year":"2014"},{"key":"10.1136\/ard-2022-223429_bib56","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223429_bib57","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/acr.24403","article-title":"Mortality among patients with polymyalgia rheumatica: a retrospective cohort study","volume":"73","author":"Partington","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223429_bib58","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/rheumatology\/keab507","article-title":"All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study","volume":"61","author":"Therkildsen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib59","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","article-title":"\u201cI suddenly felt I'd aged\u201d: a qualitative study of patient experiences of polymyalgia rheumatica (PMR)","volume":"98","author":"Twohig","year":"2015","journal-title":"Patient Educ Couns"},{"key":"10.1136\/ard-2022-223429_bib60","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/rheumatology\/keab921","article-title":"Tolerance of glucocorticoids in giant cell arteritis: a study of patient-reported adverse events","volume":"61","author":"de Boysson","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib61","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib62","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a delphi-based expert consensus","volume":"70","author":"Dejaco","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League against rheumatism\/American college of rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib65","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.semarthrit.2020.09.009","article-title":"Risk profiling for a refractory course of giant cell arteritis: the importance of age and body weight: \u201crisk profiling for GC resistance in GCA.\u201d","volume":"50","author":"Liozon","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib66","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1093\/rheumatology\/keaa894","article-title":"Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis","volume":"60","author":"Quinn","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib67","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18 f-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib68","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/art.42290","article-title":"Association of 18 f-fluorodeoxyglucose-positron emission tomography activity with angiographic progression of disease in large vessel vasculitis","volume":"75","author":"Quinn","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib69","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/rheumatology\/keab871","article-title":"Increased risk of thoracic aortic complications among patients with giant cell arteritis: a nationwide, population-based cohort study","volume":"61","author":"Therkildsen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib70","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.151024","article-title":"Which patients with giant cell arteritis will develop cardiovascular or cerebrovascular disease? A clinical practice research datalink study","volume":"43","author":"Robson","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib71","first-page":"753","article-title":"Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK clinical practice research Datalink","volume":"56","author":"Li","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib72","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1136\/annrheumdis-2013-203322","article-title":"Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation)","volume":"73","author":"Garc\u00eda-Mart\u00ednez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001003","article-title":"Systematic literature review Informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis","volume":"5","author":"Monti","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223429_bib74","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00296-014-2972-8","article-title":"Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity","volume":"34","author":"Haliloglu","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223429_bib75","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1136\/ard.2009.124958","article-title":"Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice","volume":"69","author":"van der Goes","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib76","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the giant cell arteritis actemra (giacta) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib77","doi-asserted-by":"crossref","first-page":"32","DOI":"10.55563\/clinexprheumatol\/gdps1r","article-title":"Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica?","volume":"39","author":"Marsman","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223429_bib78","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1620\/tjem.251.125","article-title":"High relapse rate in patients with polymyalgia rheumatica despite the combination of immunosuppressants and prednisolone: a single center experience of 89 patients","volume":"251","author":"Okazaki","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"10.1136\/ard-2022-223429_bib79","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/1756-185X.13978","article-title":"Predictors of glucocorticoid-free remission in patients with polymyalgia rheumatica treated with prednisolone","volume":"23","author":"Hattori","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib80","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/01.md.0000145366.40805.f8","article-title":"Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ard-2022-223429_bib81","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2020.11.003","article-title":"Prevalence and prognostic factors for aortic dilatation in giant cell arteritis-a longitudinal study","volume":"51","author":"Jud","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","article-title":"Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database","volume":"38","author":"Albrecht","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard-2022-223429_bib83","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.semarthrit.2021.01.007","article-title":"Giant cell arteritis: a nationwide, population-based cohort study on incidence, diagnostic imaging, and glucocorticoid treatment","volume":"51","author":"Therkildsen","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-223429_bib84","article-title":"Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR cohort study","volume":"5","author":"Sokhal","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1136\/ard-2022-223429_bib85","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2022-223429_bib86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib87","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib88","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"10.1136\/ard-2022-223429_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000570","article-title":"Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients","volume":"3","author":"Prieto-Gonz\u00e1lez","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223429_bib91","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","article-title":"Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis","volume":"58","author":"van Sleen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2022-223429_bib92","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/annrheumdis-2020-218697","article-title":"Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries","volume":"80","author":"Dejaco","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223429_bib93","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2665-9913(20)30386-6","article-title":"Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective","volume":"3","author":"Mackie","year":"2021","journal-title":"Lancet Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724003881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:19:43Z","timestamp":1739503183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724003881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0003496724003881"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223429","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}